| Date | Title | Description |
| 17.09.2026 | The Melanoma Research Foundation Launches its Annual Los Angeles 5K Fundraiser with a Goal of $100,000 in Support of Melanoma Research, Education and Advocacy | The Melanoma Research Foundation (MRF) is excited to announce the next stop in its annual Miles for Melanoma 5K series, uniting melanoma patients, survivors, caregivers and supporters across the Los Angeles community. This year we will be h... |
| 15.09.2026 | Gaucher Disease Drugs Market to Reach $4.3 Billion by 2036 as Long-Term Treatment and New Type 3 Therapies Reshape Rare-Disease Care | Enzyme replacement therapy leads with 58% share while Type 1 Gaucher disease accounts for 67% of 2026 demand
ROCKVILLE, Md., September 15, 2026 — The Gaucher disease treatment landscape is entering a new phase as established enzyme replacem... |
| 14.09.2026 | Pediatric Vaccines Market Expected to Reach USD 56.06 Billion by 2031 as Immunization Programs and Multivalent Vaccines Expand | Pediatric Vaccines Market Overview
According to Mordor Intelligence, the Pediatric Vaccines Market Size was valued at USD 40.24 billion in 2025 and is estimated to grow from USD 42.53 billion in 2026 to reach USD 56.06 billion by 2031, at a... |
| 10.09.2026 | PW Consulting: Global Sedative-Hypnotic Drug Market Hits $4.85B in 2025, Projected 5.85% CAGR to 2032 | Navigating the Global Sedative-Hypnotic Drug Market: Strategic Imperatives for 2026 and Beyond
The global healthcare landscape is undergoing a significant transformation, driven by an aging population, increasing prevalence of sleep disorde... |
| 09.09.2026 | Novartis-Pfizer trademark deal has opposite impact on their stock prices; Novartis India jumps 20% while Pfizer slips 3% | - |
| 04.09.2026 | Bone and Joint Health Supplements Market Trends: Aging Population and Preventive Healthcare Driving Growth | The bone and joint health supplements market is experiencing strong growth as consumers increasingly focus on preventive healthcare, active lifestyles, and maintaining musculoskeletal health. Supplements containing vitamins, minerals, colla... |
| 04.09.2026 | Trump and Kennedy’s health industry deals haven’t been enforced and are at risk of vanishing | Getting your Trinity Audio player ready...
By Stephanie Armour, KFF Health News
In the thick of his competitive reelection race in Michigan, Republican Rep. Tom Barrett joined Health and Human Services Secretary Robert F. Kennedy Jr. at a s... |
| 02.09.2026 | Top US doctors offer updated flu and COVID vaccine recommendations, aiming to ease confusion | Getting your Trinity Audio player ready...
By LAURAN NEERGAARD, AP Medical Writer
Leading U.S. medical groups are urging people to get updated flu and COVID-19 vaccinations this fall, banding together Wednesday to issue shot guidelines — an... |
| 01.09.2026 | Sun Pharma signs deal with US government to reduce drug prices | Drug major Sun Pharmaceutical Industries has signed a deal with the US government to lower prices of its innovative drugs in the US, in line with the lowest prices paid by other developed nations, under the most favoured nation (MFN) pricin... |
| 28.08.2026 | Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's | HONG KONG, Aug. 28, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced its 2026 interim results. During the reporting period, the Company achieved record-high drug sales revenue, further adva... |
| 25.08.2026 | Innovent Announces 2026 Interim Results and Business Updates | Transforming from Regional Leader to Global Premier:
A Clear Strategic Path for Growth and Globalization
SAN FRANCISCO and SUZHOU, China, Aug. 25, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biophar... |
| 20.08.2026 | Bristol Myers Squibb Partners with Chai Discovery for AI Antibody Design | What You Should Know
Chai Discovery announced a strategic biopharmaceutical collaboration with Bristol Myers Squibb (BMS) to advance the discovery and engineering of therapeutic antibodies using artificial intelligence.
Bristol Myers Squibb... |
| 19.08.2026 | Российская фармкомпания стала лидером по выплатам врачам и медорганизациям | Российская фармкомпания стала лидером по выплатам врачам и медорганизациям Иностранные игроки все меньше тратят на исследования
«Р-Фарм» потратил на выплаты врачам и организациям в 2025 году 2,2 млрд руб., больше, чем любой другой член Ассо... |
| 14.08.2026 | Включение новых препаратов в ЖНВЛП сэкономило бюджету 2 млрд рублей | Включение новых препаратов в ЖНВЛП сэкономило бюджету 2 млрд рублей
Включение восьми новых препаратов в перечень жизненно необходимых и важнейших лекарственных препаратов (ЖНВЛП) позволило сэкономить бюджету 2 млрд руб. в первом полугодии 2... |
| 14.08.2026 | Pharmaceuticals Market Trends: Innovation, Rising Healthcare Demand, and Advanced Therapies Driving Growth | The pharmaceuticals market is witnessing strong growth as rising healthcare needs, increasing disease prevalence, expanding access to medicines, and continuous innovation in drug development drive global demand. Pharmaceutical products play... |
| 12.08.2026 | Silent Cancer Therapeutics Market Size to Reach USD 36.52 Billion by 2035, Driven by Precision Oncology and Advanced Cancer Therapies | Overview
According to DataM Intelligence, the global silent cancer therapeutics market size was valued at USD 15.86 billion in 2025 and is forecast to reach USD 36.52 billion by 2035, expanding at a CAGR of 8.7% during 2026 to 2035. The mar... |
| 11.08.2026 | ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer | ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the appointments of Jim Wassil, currently Chief Operating Off... |
| 07.08.2026 | Monster insider trading alert for Pfizer stock |
As Pfizer Inc. (NYSE: PFE) stock gained over 5% this week fueled by its strong second quarter 2026 earnings report, Finbold has observed its increased insider trading .
Two Pfizer directors, Ronald E. Blaylock and Mortimer J. Buckley spent... |
| 05.08.2026 | Pharma Giants Eye Colossal Merger: AstraZeneca and Bristol Myers Squibb in $400 Billion Talks | AstraZeneca and Bristol Myers Squibb reportedly discuss a $400 billion pharmaceutical megamerger. This potential tie-up would reshape the industry. The news sent AstraZeneca shares down, puzzling market analysts. Many question the strategic... |
| 05.08.2026 | Biweekly GLP-1 Drug Clears First Human Test via Dual Fatty Acid Engineering | By Scott McCain
Published: Aug 05 2026, 9:01 AM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 04.08.2026 | Pfizer Q2 2026 Earnings Beat Estimates; Non-COVID Revenue Surges 18% Operationally | By Jerry Owens
Published: Aug 04 2026, 10:07 AM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 04.08.2026 | Pfizer tops estimates, hikes low end of revenue guidance on strength of Eliquis, other drugs | Pfizer reported second-quarter results that topped estimates and hiked the low end of its revenue outlook, citing an added $1.5 billion in sales from its non-Covid products.
The company is now expecting full-year revenue to total $60.5 bill... |
| 03.08.2026 | Daily Stock Market Live
Dow futures jump 400 points after strong Caterpillar and Palantir earnings, S&P 500 to make run at record: Live updates | Stock futures moved higher on Tuesday, fueled by strong quarterly results from companies such as Caterpillar and Palantir Technologies.
Nasdaq-100 futures popped about 1%, as Palantir rallied more than 15% in premarket trading on blowout re... |
| 03.08.2026 | 5 Things to Know
U.S.-Iran talks, OpenAI’s Hugging Face hack, Best Buy’s new CEO and more in Morning Squawk | This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox.
Happy Monday. I spent the weekend mostly outdoors at the Lollapalooza music festival in Chicago, but many others headed inside to catch the l... |
| 03.08.2026 | Британская AstraZeneca обсуждала с американской Bristol Myers Squibb слияние стоимостью почти $400 млрд | Британская фармацевтическая компания AstraZeneca и американская Bristol Myers Squibb (BMS) провели предварительные переговоры о возможном слиянии, которое может привести к созданию одного из крупнейших производителей лекарств в мире с совок... |
| 02.08.2026 | AstraZeneca Targets $400B Bristol Myers Squibb Merger Twelve Years After Spurning Pfizer | By Joshua Mitchell
Published: Aug 02 2026, 5:39 PM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 02.08.2026 | AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports | UK pharmaceutical company AstraZeneca is considering a deal to merge with its U.S. competitor Bristol Myers Squibb, according to a report by the Financial Times.
The megadeal would be one of the largest in history, creating a combined compa... |
| 31.07.2026 | AI Agents Invade Supply Chains: Freehand Lands $75M to Revolutionize Procurement | Freehand secured $75 million in new funding, led by Battery Ventures and NewRoad Capital Partners. This capital will scale its autonomous AI agents, revolutionizing enterprise supply chain and procurement. The technology directly tackles im... |
| 29.07.2026 | "We are a very different company to Palantir,” says “discreet” French replacement | The managing director of the little-known French startup thrown into the spotlight when it was chosen by France’s domestic intelligence services to replace controversial US data analytics giant Palantir doesn’t like the company being called... |
| 29.07.2026 | Enterprise AI firm Freehand secures $75M led by Battery Ventures, NewRoad | Freehand, a San Francisco-headquartered enterprise AI company founded by Indian entrepreneurs, has raised $75 million in a funding round co-led by Battery Ventures, a global technology-focused investment firm, and NewRoad Capital Partners, ... |
| 27.07.2026 | Harbour BioMed and Sinopharm Enter Strategic Collaboration to Establish Innovation R&D Consortium | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 27, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, o... |
| 24.07.2026 | Trump's Generic Drug Tariffs: U.S. Onshoring Push Faces Steep Challenges | U.S. faces major generic drug tariff changes. Trump announced duties up to 200% on imported generics. A two-year window encourages domestic manufacturing. This policy aims to onshore critical drug production. Industry concerns are high. Gen... |
| 24.07.2026 | Harbour BioMed Announces Positive Profit Alert for 2026 Interim Results, Marking Seventh Consecutive Profitable Half-Year as Platform-Based Advantages Drive Sustainable Growth | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 24, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therap... |
| 23.07.2026 | Cheiron Scores $8M Seed Round |
LOS ALTOS, CA, Cheiron, the operating system for drug programs, announced an $8 million seed round led by Menlo Ventures.
>> Click here for more funding data on Cheiron
>> To export Cheiron funding data to PDF and Excel, click ... |
| 22.07.2026 | Trump plans generic drug tariffs from 2028 with two-year delay testing U.S. onshoring push | Trump said generic drugs imported into the U.S. will face zero tariffs for two years from August 1.
The rate will rise to 100% in 2028, before doubling a year later.
The latest tariff salvo underscored Trump’s goals of reshoring the low-cos... |
| 20.07.2026 | PharmaBlock Convenes Global Industry Leaders in Zurich to Advance Green Chemistry for Sustainable Pharmaceutical Manufacturing | ZURICH, July 20, 2026 /PRNewswire/ -- As Europe experienced one of its hottest Junes on record, with prolonged heatwaves reinforcing the urgency of climate action, leaders from the pharmaceutical industry and academia gathered in Zurich for... |
| 20.07.2026 | What to know about testosterone replacement therapy as the U.S. military plans to test troops | Testosterone replacement therapy is back in the spotlight after the U.S. military said it will begin testing service members’ testosterone levels and make replacement therapy available to those who qualify.
The therapy is a synthetic form o... |
| 18.07.2026 | Chai Discovery Secures $400M, Propelling AI-Driven Molecular Design | Chai Discovery secured a $400 million Series C funding round. This elevates its valuation to $3.8 billion. The capital injection accelerates its AI-driven molecular design platform. Chai transforms drug discovery, shifting from trial-and-er... |
| 17.07.2026 | DIMERIX EXPANDS PIPELINE WITH ACQUISITION OF PHASE 2 READY ASSET FOR ACUTE KIDNEY INJURY | Highlights
Dimerix acquires Phase 2-ready asset, DMX-652 - with potential for rapid advancement into a Phase 2 clinical study under an open US Investigational New Drug (IND) application, with initial focus on acute kidney injury (AKI)
DMX-6... |
| 17.07.2026 | The Melanoma Research Foundation Launches its Annual Cleveland 5K Fundraiser with a Goal of $155,000 in Support of Melanoma Research, Education and Advocacy | The Melanoma Research Foundation (MRF) is excited to announce the next stop in its annual Miles for Melanoma 5K series, uniting melanoma patients, survivors, caregivers and supporters across the Cleveland community. This year we will be hos... |
| 16.07.2026 | When Biological Indicators Don’t Fit: Rethinking Sterility Testing in Oncology Manufacturing | Share
Share
Share
Share
Email
Pfizer validation engineer, peer-reviewed author, and ASTM Committee E55.06 voting member Prasantha Pujari on solving qualification challenges where biologics meet cytotoxic drugs — and why the frameworks he bu... |
| 16.07.2026 | Calcbench: 72 percent of S&P 500 companies reported adjusted earnings in 2025, pushing non-GAAP net income higher than "traditional" GAAP net income by $271 billion | Adjustments to earnings remain widespread across Corporate America. S&P 500 companies routinely report "adjusted earnings." Just how much companies are adjusting, and the substance of those adjustments, are the subject of a co... |
| 15.07.2026 | Половые трудности | Половые трудности Почему растут продажи гормонов и смежных препаратов
Позднее родительство, развитие вспомогательных репродуктивных технологий (ВРТ), рост интереса мужчин к гормональной терапии и более осознанное отношение женщин к репродук... |
| 15.07.2026 | Минздрав впервые зарегистрировал препарат по итогам инспекции за рубежом | Минздрав впервые зарегистрировал препарат по итогам инспекции за рубежом Eisai получила регудостоверение, хотя не проводила клинисследований в России
Японская фармкомпания Eisai 1 июля получила регудостоверение на свой новый препарат против... |
| 15.07.2026 | Lynk Pharmaceuticals Announces Completion of Patient Enrollment in Phase III Clinical Trial of Zemprocitinib for Ankylosing Spondylitis | HANGZHOU, China and SHANGHAI and BOSTON, July 15, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, toda... |
| 15.07.2026 | ACROBiosystems Obtains PMDA Material Suitability Confirmation for GMP-grade IL-15, Ensuring Reliable Quality and Strengthening the Biopharmaceutical Approval Process | NEWARK, Del., July 15, 2026 /PRNewswire/ -- Recently, ACROBiosystems has officially received the "Material Suitability Confirmation for Regenerative Medicine Products" (Certificate No.: 薬機審長発第47号) from the Pharmaceuticals and Medi... |
| 14.07.2026 | Chai Discovery nabs $400M Series C as AI-designed antibodies reach Big Pharma | Chai Discovery Inc., a company that develops artificial intelligence models to predict interactions between biochemical molecules, today announced it has raised $400 million in new funding, nearly tripling its valuation to $3.8 billion.
Ind... |
| 14.07.2026 | Chai Discovery Raises $400M to Accelerate AI-Driven Molecular Design Platform | What You Should Know
Structural biology and AI drug design pioneer Chai Discovery has announced a $400M Series C funding round, valuing the company at $3.8 billion just two years after its 2024 founding.
The heavily oversubscribed round was... |
| 14.07.2026 | Chai Discovery Raises $400 Million Series C To Advance AI-Driven Molecular Design | Chai Discovery announced a $400 million Series C financing to accelerate the development and deployment of its AI-driven molecular design platform. The round valued Chai Discovery at $3.8 billion. It was led by Index Ventures alongside Klei... |
| 13.07.2026 |
Jim Cramer says tech remains the market’s best place to find big winners despite recent struggles | Monday - Friday, 6:00 - 7:00 PM ET
CNBC’s Jim Cramer said tech stocks continue to offer the market’s biggest upside because companies can quickly create new catalysts that reshape their valuations.
He pointed to Meta, SK Hynix and Alphabet ... |
| 13.07.2026 | Would hunters take a Lyme disease vaccine? We asked | Getting your Trinity Audio player ready...
By Bram Sable-Smith, KFF Health News
It’s tick season, possibly the worst in a decade.
More and more Americans are being exposed to these parasites as climate change expands the range where they ca... |
| 13.07.2026 | Longevity Gene Therapy Holds in Aged Dogs: Pfizer COVID Vaccine LNP Partner Backs SIRT6 Platform | By Mike Gonzales
Published: Jul 13 2026, 11:06 AM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 12.07.2026 | AstraZeneca's Pipeline Premium Challenged After Wainua Trial Failure | AstraZeneca faced a rare clinical failure with its Wainua drug in a late-stage trial for ATTR cardiomyopathy. Shares plunged significantly, well beyond the drug's estimated financial impact. This event challenges the pharmaceutical giant's ... |
| 10.07.2026 | «Круг добра» будет обеспечивать терапией детей с врожденным ихтиозом | «Круг добра» будет обеспечивать терапией детей с врожденным ихтиозом
Экспертный совет фонда «Круг добра» одобрил включение врожденного ихтиоза в перечень заболеваний, лечение которых оплачивает фонд. После утверждения решения попечительским... |
| 09.07.2026 | Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial of LNK01004 Ointment for Vitiligo | HANGZHOU, China, SHANGHAI and BOSTON, July 9, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, today an... |
| 09.07.2026 | AstraZeneca stock drops 9% after heart drug trial miss deals rare blow to pharma powerhouse | AstraZeneca’s medicine Wainua did not meet its goal of reducing deaths and recurrent heart-related emergencies in people with a rare heart condition.
Shares slumped and were on track for the worst day in over six years.
Jefferies analysts s... |
| 09.07.2026 | Immunotherapy Drugs Market to Reach $580.6 Billion by 2029 | The global Immunotherapy drugs market is projected to grow from USD 285.3 billion in 2024 to USD 580.6 billion by 2029, at a robust CAGR of 15.3% during the forecast period. Market growth is driven by advancements in antibody engineering te... |
| 08.07.2026 | Unstable New York City skyscraper sparks major Manhattan evacuation | NEW YORK: Emergency crews evacuated a busy Manhattan street block during the Tuesday (Jul 7) morning rush hour after structural columns buckled inside a skyscraper undergoing construction work, officials said.
The former head office of the ... |
| 07.07.2026 | BIOHK2026 (Hong Kong International Biotechnology Conference and Exhibition), 9-12 September, Hong Kong - Connecting Global Leaders in Biotechnology | Seeking biotech investment, breakthrough innovations, or a strategic gateway to the Asia-Pacific? The answers await in Hong Kong this September.
HONG KONG, July 7, 2026 /PRNewswire/ -- The 5th Hong Kong International Biotechnology Conferenc... |
| 07.07.2026 | Manhattan high-rise deemed stable after columns buckled, and some evacuations are lifted | Getting your Trinity Audio player ready...
By PHILIP MARCELO and ANTHONY IZAGUIRRE
NEW YORK (AP) — An under-construction Manhattan high-rise at risk of collapse was stabilized late Tuesday and some evacuations of nearby buildings were lifte... |
| 06.07.2026 | HSBC Drops Pfizer to Hold: Seagen ADC Miss Leaves $43B Bet Without Catalyst | By Adrian Parham
Published: Jul 06 2026, 11:58 AM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 02.07.2026 | Oblenio Bio Secures $62M to Advance Autoimmune Immune Reset Therapy LBL-051 into Clinic | Oblenio Bio raised $62 million in Series B funding. Pfizer Ventures led the round, with Deep Track Capital and GV joining. Funds will advance LBL-051, a tri-specific T-cell engager, into clinical development. LBL-051 targets refractory auto... |
| 30.06.2026 | Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China | SAN FRANCISCO and SUZHOU, China, June 30, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for... |
| 30.06.2026 | Nike results top estimates even as China sales drop 12%; retailer expects $986 million tariff refund | Nike reported earnings and revenue that beat Wall Street expectations.
Still, the company reported a 12% drop in sales in its Greater China market.
Nike also said its gross margin increased 8.9% during the quarter, largely due to an expecte... |
| 29.06.2026 | Prostate Cancer Drug Cuts Progression Risk by 52%: Genetic Test Required | By Mireya Ramsey
Published: Jun 29 2026, 11:47 PM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 27.06.2026 | Oblenio Bio Raises $62 Million Series B To Advance Autoimmune Disease Therapy | Oblenio Bio announced that it has closed an oversubscribed $62 million Series B financing round to advance its lead autoimmune disease program into clinical development. The round was led by Pfizer Ventures, with participation from new inve... |
| 24.06.2026 | UK Navigates Leadership Shift Amid Economic Headwinds and Tech Push | The UK charts a new course. Andy Burnham assumes the premiership. Markets eye his fiscal strategies. Economic headwinds persist. Brexit's long-term impacts surface. Retailers battle online giants. Government targets outsourcing, consumer fr... |
| 24.06.2026 | Tarek Samad appointed EVP, Head of Research & Development at Lundbeck | VALBY, Denmark, June 24, 2026 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) today announced that Tarek Samad has been appointed Executive Vice President and Head of Research & Development (R&D) and will join the Executive Leadership Te... |
| 22.06.2026 | WEF’s ‘Summer Davos’ in Dalian to focus on unlocking economic growth through innovations | Listen
6 min
New: You can now listen to articles.
This audio is generated by an AI tool.
DALIAN, China: The search for new drivers of economic growth will take centre stage at the World Economic Forum's (WEF) Summer Davos meeting in the nor... |
| 19.06.2026 | Gero Raises $17 Million To Slow Aging | Gero announced it has raised $17 million in new financing, bringing its total equity funding to $34 million. The company is developing medicines designed to slow aging and treat age-related diseases by combining longitudinal human data, AI,... |
| 19.06.2026 | Regulator wins decade-long pricing tussle with Pfizer | The UK competition watchdog has won permission to appeal in a case against US pharmaceutical giant Pfizer after a long-running legal battle over allegations of excessive pricing, overturning a previous decision by the Tribunal.
The court sa... |
| 18.06.2026 | FDA Clears CAPVAXIVE for Chronically Ill Children: Vaccine Covers 11 Strains Rivals Miss | By Maxwell Templeton
Published: Jun 18 2026, 09:38 AM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 16.06.2026 | Amferia Annual General Meeting (AGM) Appoints Global Healthcare Leaders Randy Schwartz and Nikolaj Sørensen to Board of Directors | Amferia Annual General Meeting (AGM) Appoints Global Healthcare Leaders Randy Schwartz and Nikolaj Sørensen to Board of Directors
Tue, Jun 16, 2026 10:18 CET Report this content
Amferia AB is pleased to announce the appointment of two new b... |
| 16.06.2026 | Dataiku Announces Cobuild General Availability, the AI Building Agent That Closes the Build-Govern Gap | Dataiku Cobuild closes the enterprise AI execution gap, transforming plain-language business intent into inspectable, governed AI projects that teams can trust from the start
SINGAPORE, June 16, 2026 /PRNewswire/ -- Dataiku, the Platform fo... |
| 16.06.2026 | Colorado receives FDA permission to import cheaper drugs — including Ozempic — from Canada | Getting your Trinity Audio player ready...
Colorado finally has federal permission to start importing cheaper prescription drugs from Canada, but the state may not have any sellers to work with.
Lawmakers passed a bill in 2019 that directed... |
| 13.06.2026 | Drugmakers race to find a place in the next wave of obesity drugs | Eli Lilly, Novo Nordisk, Amgen, Zealand, Structure Therapeutics shared their visions for the future of obesity medicine.
Drugmakers pitched doctors and investors on their future drugs at the recent American Diabetes Association (ADA) Scient... |
| 13.06.2026 | Intelegain Marks 26 Years of Transforming Enterprises Through Technology | Share
Share
Share
Share
Email
Mumbai, India — June 2026
Twenty-six years is a long time in any industry. In enterprise technology, it’s a lifetime. When Intelegain started out, businesses were still figuring out the internet. Desktop softwa... |
| 10.06.2026 | Lynk Pharmaceuticals' Partner Formation Bio Doses First Participant in Phase 1 Trial of BLKR201 (originally designated as LNK01006), a CNS-Penetrant TYK2 Inhibitor | HANGZHOU, China, SHANGHAI and BOSTON, June 10, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on autoimmune and inflammatory diseases, tod... |
| 08.06.2026 | Pfizer Berobenatide ADA Data: Monthly Dosing Aims at Wegovy, but Weight Loss Trails Zepbound | By Maxwell Templeton
Published: Jun 08 2026, 11:36 AM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 08.06.2026 | Obesity Drug Pipeline at ADA 2026: Retatrutide Matches Bariatric Surgery, Monthly GLP-1 Debuts | By Chase Fiorini
Published: Jun 08 2026, 09:59 AM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 08.06.2026 | Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide | NEW ORLEANS, June 8, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences"), a commercial-stage biopharmaceutical company focused on discovering and developing innovative therapies for metabolic diseas... |
| 05.06.2026 | LivaNova Appoints Anne Liddy as Chief Legal Officer | LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced the appointment of Anne Liddy as Chief Legal Officer, effective August 31. Liddy will oversee the Company’s global legal and compliance function and s... |
| 01.06.2026 | Lynk Pharmaceuticals Announces NMPA Approval of LNK01004 Ointment's Phase II Clinical Trial for the Treatment of Vitiligo and Chronic Hand Eczema | HANGZHOU, China, SHANGHAI and BOSTON, June 1, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, today an... |
| 29.05.2026 | Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines | SAN FRANCISCO and NEW YORK, and SUZHOU, China, May 29, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (01801.HK) and Pfizer Inc. (NYSE: PFE), today announced the companies have entered into a strategic global licensing and collaboration agre... |
| 29.05.2026 | Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion | The partnership includes licensing, co-development, and co-commercialization opportunities across a diverse portfolio of antibody-drug conjugates.
Innovent will will co-commercialize with Pfizer in the U.S. and Europe and share profits but ... |
| 29.05.2026 | Innovent Biologics: Up To $10.5 Billion Oncology Collaboration With Pfizer | Innovent Biologics announced a global strategic licensing and collaboration agreement with Pfizer focused on the research and development of 12 early-stage and de novo oncology programs, creating one of the largest oncology partnerships ann... |
| 23.05.2026 | The Melanoma Research Foundation Launches its Annual Denver 5K Fundraiser with a Goal of $100,000 in Support of Melanoma Research, Education and Advocacy | The Melanoma Research Foundation (MRF) is excited to announce the next stop in its annual Miles for Melanoma 5K series, uniting melanoma patients, survivors, caregivers and supporters across the Denver community. This year we will be hostin... |
| 18.05.2026 | Gradiant Closes Series E Funding, at $2 Billion Valuation | Gradiant, a Boston, MA-based provider of advanced water and wastewater treatment solutions, raised an undisclosed amount in Series E funding, at $2M Billion valuation.
The round was led by Safar Partners and Hostplus Superannuation Fund, wi... |
| 11.05.2026 | CellCentric Secures $220M to Accelerate Myeloma Drug Inobrodib | CellCentric secured $220 million in Series D funding. This capital fuels pivotal clinical trials for inobrodib. Inobrodib is a novel oral p300/CBP inhibitor. It targets relapsed or refractory multiple myeloma. Phase 2 data demonstrated sign... |
| 10.05.2026 | ACROBiosystems Launches Global License Solution Upgrade for HEK293 Functional Cell Lines, Streamlining Compliance to Accelerate Biopharmaceutical R&D | NEWARK, Del., May 10, 2026 /PRNewswire/ -- ACROBiosystems has implemented a major upgrade to its global licensing framework for HEK293 functional cell lines, transitioning from a complex administrative process to a streamlined, purchase-bas... |
| 10.05.2026 | Quantum firm hailed by Amgen tech leader as an ‘extraordinary platform’ plans IPO | A quantum tech firm that has collaborated with—and received investment from—Amgen is now planning to go public.
Quantinuum was created in 2021 when industrial manufacturing juggernaut Honeywell spun off its quantum computing hardware busine... |
| 07.05.2026 | CellCentric: $220 Million Series D Raised To Advance Inobrodib Trials For Multiple Myeloma | CellCentric announced the completion of an oversubscribed $220 million Series D financing to support pivotal clinical trials of inobrodib, the company’s first-in-class oral p300/CBP inhibitor for the treatment of multiple myeloma.
The finan... |
| 07.05.2026 | For the Reasons that Matter: A Multi-Spotlight Campaign Puts Adult Respiratory Health in Focus | JAKARTA, Indonesia, May 7, 2026 /PRNewswire/ -- In conjunction with World Immunization Week, Pfizer Indonesia, together with healthcare professionals has launched "For the Reasons that Matter", a public awareness campaign focused ... |
| 04.05.2026 | 5 Things to Know
Berkshire Hathaway meeting, Spirit shuts down, Meta’s return to court and more in Morning Squawk | This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox.
Happy Monday. Congratulations to Golden Tempo on winning the Kentucky Derby. However, as a financial journalist, I felt inclined to root for ... |
| 30.04.2026 | For the Reasons that Matter: A First‑of‑Its‑Kind Multi-Country Campaign Spotlights Adult Respiratory Health | A first-of-its-kind multi-country adult respiratory health awareness campaign is now live across Singapore, Malaysia, Indonesia, and the Philippines
SINGAPORE, April 30, 2026 /PRNewswire/ -- In conjunction with World Immunisation Week, Pfiz... |
| 30.04.2026 | ACROBiosystems and SeromYx Systems Announce Strategic Collaboration on Comprehensive Functional Profiling of Anti-CD20 Monoclonal Antibodies | TOKYO and NEWARK, Del., April 30, 2026 /PRNewswire/ -- ACROBiosystems, a company dedicated to being a cornerstone of the global biopharmaceutical and healthcare industries, has entered into a research collaboration with SeromYx Systems, spe... |
| 28.04.2026 | ACROBiosystems Wins CiteAb Award, Gaining Worldwide Recognition | SAN DIEGO and NEWARK, Del., April 28, 2026 /PRNewswire/ -- Recently, ACROBiosystems was honored as a "Protein Supplier to Watch in Cancer Research in 2026" at the CiteAb Awards.
CiteAb accelerates scientific research by providing ... |
| 28.04.2026 | ACROBiosystems Showcases AI-Driven Innovation at AACR 2026, Empowering Next-Generation Biologics Discovery | SAN DIEGO and NEWARK, N.J., April 28, 2026 /PRNewswire/ -- From April 17 to 22, 2026, ACROBiosystems—a company dedicated to being a cornerstone of the global biopharmaceutical and healthcare industries—presented its comprehensive, AI‑driven... |
| 24.04.2026 | Iridius: $8.6 Million Seed Funding Raised To Build Compliance-By-Design AI Platform For Regulated Industries | Iridius, a compliance-by-design AI platform for regulated workflow execution, has raised $8.6 million in seed funding led by Chalfen Ventures, with participation from Osage Venture Partners, Accenture Ventures, and Rock Yard Ventures. Separ... |
| 19.04.2026 | Helical Secures $10M for AI-Powered Drug Discovery Lab | Helical has successfully raised $10 million in seed funding. This investment propels its groundbreaking virtual AI lab for pharmaceutical research. The platform bridges a crucial gap: translating powerful biological foundation models into d... |
